Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALP009
MIFTS: 66

Alopecia Areata

Categories: Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Alopecia Areata

About this section

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 77 54 26 56 6 45 15 17 74
Alopecia Circumscripta 54 26
Cazenave's Vitiligo 54 74
Jonston's Alopecia 54 74
Marginal Alopecia 54 74
Celsus' Vitiligo 54 74
Diffuse Alopecia 54 74
Patchy Alopecia 54 6
Alopecia Celsi 54 74
Aa 54 26
Circumscribed Alopecia 12
Alopecia Cicatrisata 54
Pseudopelade 74
Alopecia 74

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


Sources

Summaries for Alopecia Areata

About this section
NIH Rare Diseases : 54 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. This condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. There is no cure or approved therapy for AA; however, some people find that medications approved for other purposes can help regrow hair.

MalaCards based summary : Alopecia Areata, also known as alopecia circumscripta, is related to aplastic anemia and vitiligo-associated multiple autoimmune disease susceptibility 1, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia Areata is TRPS1 (Transcriptional Repressor GATA Binding 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Clobetasol and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An autoimmune hypersensitivity disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Genetics Home Reference : 26 Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.

Wikipedia : 77 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Sources

Related Diseases for Alopecia Areata

About this section

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 575)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 32.3 FASLG IFNG IL2 TNF
2 vitiligo-associated multiple autoimmune disease susceptibility 1 31.6 AIRE CTLA4 PTPN22
3 contact dermatitis 31.0 ICAM1 IFNG IL1A TNF
4 lichen planus 30.9 GZMB ICAM1 IFNG TNF
5 candidiasis 30.9 AIRE IFNG IL17A
6 myasthenia gravis 30.9 AIRE CTLA4 IFNG IL2 TNF
7 dermatitis, atopic 30.8 ICAM1 IFNG IL17A IL2 TNF
8 thyroiditis 30.7 CTLA4 FASLG IL2 PTPN22
9 temporal arteritis 30.7 IFNG IL1RN PTPN22 TNF
10 celiac disease 1 30.6 CTLA4 GZMB KLRK1 PTPN22
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 AIRE CTLA4 IFNG IL17A PTPN22
12 ulcerative colitis 30.5 IFNG IL17A IL2 TNF
13 lymphopenia 30.5 FASLG IFNG IL2 IL2RA
14 allergic contact dermatitis 30.5 ICAM1 IFNG IL17A TNF
15 arthritis 30.4 IFNG IL17A IL1A IL1RN PTPN22 TNF
16 chronic graft versus host disease 30.4 IFNG IL1A IL2RA TNF
17 sarcoidosis 1 30.4 IFNG IL2 IL2RA TNF
18 colitis 30.4 CTLA4 IFNG IL17A IL2 TNF
19 mycosis fungoides 30.4 CTLA4 CXCL10 GZMB IL2 IL2RA
20 autoimmune disease 30.4 AIRE CTLA4 IFNG IL17A IL2 IL2RA
21 intermediate uveitis 30.3 IFNG IL2 IL2RA TNF
22 juvenile rheumatoid arthritis 30.3 IL1RN IL2RA TNF
23 acquired immunodeficiency syndrome 30.3 IFNG IL2 IL2RA TNF
24 psoriatic arthritis 30.3 IL17A IL1A PTPN22 TNF
25 spondylitis 30.3 IL17A IL1RN TNF
26 chronic mucocutaneous candidiasis 30.2 AIRE IFNG IL17A IL2RA PTPN22 TNF
27 cutaneous lupus erythematosus 30.2 GZMB ICAM1 TNF
28 keratoconjunctivitis 30.2 ICAM1 IFNG IL2 TNF
29 inflammatory bowel disease 30.2 IFNG IL17A IL2 TNF
30 graves' disease 30.2 CTLA4 FASLG ICAM1 IFNG IL2RA PTPN22
31 aggressive periodontitis 30.2 IL1A IL1RN TNF
32 rheumatic disease 30.1 IFNG IL2RA TNF
33 leishmaniasis 30.0 IFNG IL1A TNF
34 conjunctivitis 30.0 ICAM1 IFNG IL2
35 human immunodeficiency virus infectious disease 29.9 IFNG IL2 TNF
36 lepromatous leprosy 29.9 ICAM1 IFNG IL2 TNF
37 visceral leishmaniasis 29.9 IFNG IL2 TNF
38 periodontitis 29.9 IFNG IL17A IL1A TNF
39 mumps 29.9 IFNG IL2 IL2RA TNF
40 filariasis 29.9 CTLA4 IFNG IL2 TNF
41 spondyloarthropathy 29.8 IFNG IL17A TNF
42 echinococcosis 29.8 IFNG IL17A TNF
43 hashimoto thyroiditis 29.8 AIRE CTLA4 FASLG ICAM1 IFNG IL2RA
44 common variable immunodeficiency 29.7 CTLA4 IFNG IL2 IL2RA TNF
45 uveitis 29.7 CTLA4 CXCL10 ICAM1 IFNG IL17A IL1A
46 graft-versus-host disease 29.7 FASLG GZMB IFNG IL1A IL2 TNF
47 diabetes mellitus 29.7 AIRE CTLA4 FASLG IFNG IL1A IL1RN
48 erythema multiforme 29.7 FASLG GZMB ICAM1 IFNG IL2 TNF
49 relapsing-remitting multiple sclerosis 29.6 ICAM1 IFNG IL17A TNF
50 periodontal disease 29.6 IL17A IL1A IL1RN TNF

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata
Sources

Symptoms & Phenotypes for Alopecia Areata

About this section

UMLS symptoms related to Alopecia Areata:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 GZMB ICAM1 IL17A IL1A IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 GZMB ICAM1 IL17A IL1A IL2 IL2RA

MGI Mouse Phenotypes related to Alopecia Areata:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
2 homeostasis/metabolism MP:0005376 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
3 digestive/alimentary MP:0005381 10.22 AIRE CTLA4 FASLG ICAM1 IFNG IL17A
4 immune system MP:0005387 10.21 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
5 cardiovascular system MP:0005385 10.19 CTLA4 CXCL10 FASLG ICAM1 IFNG IL1A
6 endocrine/exocrine gland MP:0005379 10.16 AIRE CTLA4 FASLG ICAM1 IFNG IL17A
7 mortality/aging MP:0010768 9.97 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
8 integument MP:0010771 9.92 CTLA4 FASLG ICAM1 IFNG IL1A IL1RN
9 liver/biliary system MP:0005370 9.8 AIRE CTLA4 FASLG IFNG IL2 PTPN22
10 neoplasm MP:0002006 9.5 AIRE FASLG ICAM1 IFNG IL1A IL2
11 respiratory system MP:0005388 9.32 AIRE CTLA4 FASLG IFNG IL17A IL2
Sources

Drugs & Therapeutics for Alopecia Areata

About this section

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 524)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 5311051 32798
2
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
4
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 38304-91-5 4201
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
13
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
14
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
15
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
18
Hydroxychloroquine Approved Phase 4 118-42-3 3652
19
Capsaicin Approved Phase 4,Not Applicable 404-86-4 1548943
20 Orange Approved Phase 4,Phase 1,Not Applicable
21
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
22
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
23
Aminolevulinic acid Approved Phase 4,Phase 3,Not Applicable 106-60-5 137
24
Drospirenone Approved Phase 4 67392-87-4 68873
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
26
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 6473866 445643 439492
27
tannic acid Approved Phase 4,Phase 3,Phase 2 1401-55-4
28
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
30
Hydroxocobalamin Approved Phase 4,Phase 1 13422-51-0 15589840 11953898
31
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 1 13422-55-4
32
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
33
Ketoconazole Approved, Investigational Phase 4,Phase 3 65277-42-1 47576
34
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
35
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 477600-75-2
36
Abatacept Approved Phase 4,Phase 2 332348-12-6 10237
37
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
38
Desogestrel Approved Phase 4 54024-22-5 40973
39
Levonorgestrel Approved, Investigational Phase 4,Phase 3 797-63-7, 17489-40-6 13109
40
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
41
Apremilast Approved, Investigational Phase 4,Phase 2,Not Applicable 608141-41-9 11561674
42
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
43
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
44
Warfarin Approved Phase 4 81-81-2 54678486 6691
45
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
47
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
48
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 1 68-19-9 44176380
49
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 60-18-4 6057
50
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7

Interventional clinical trials:

(show top 50) (show all 698)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
3 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
5 Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
6 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
7 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
8 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
9 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
10 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
12 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
13 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
14 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
16 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
17 The Vienna Prograf and Endothelial Progenitor Cell Study Completed NCT00182559 Phase 4 Ciclosporin;Tacrolimus
18 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
19 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
20 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
21 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Recruiting NCT03800979 Phase 4 Tofacitinib
22 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
23 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
24 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
25 Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
26 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
27 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
28 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
29 Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant Active, not recruiting NCT03353012 Phase 4 Etonogestrel Drug Implant;Levonorgestrel Drug Implant
30 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
31 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
32 Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
33 DANWARD - Danish Warfarin-Dialysis Study Not yet recruiting NCT03862859 Phase 4 Warfarin
34 Pentoxifylline in Lupus Nephritis Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
35 Intralesional Steroids in the Treatment of Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
36 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
37 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
38 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
39 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
40 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
41 Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
42 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Unknown status NCT01671384 Phase 3 Valproate, Levocarnitine;Placebo
43 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
44 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
45 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
46 The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Completed NCT02037191 Phase 3 Methotrexate;Placebo
47 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
48 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
49 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
50 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: alopecia areata

Sources

Genetic Tests for Alopecia Areata

About this section
Sources

Anatomical Context for Alopecia Areata

About this section

MalaCards organs/tissues related to Alopecia Areata:

42
Lung, Breast, T Cells, Skin, Brain, Thyroid, Ovary
Sources

Publications for Alopecia Areata

About this section

Articles related to Alopecia Areata:

(show top 50) (show all 2196)
# Title Authors Year
1
Allergic contact dermatitis probably caused by latanoprost during treatment for alopecia areata. ( 30663070 )
2019
2
Laparoscopic Extirpation of Adrenal Gland Ganglioneuroma Incidentally Diagnosed During Evaluation for Patchy Alopecia Areata in an Adolescent Boy. ( 30897574 )
2019
3
Increasing prevalence of alopecia areata in South Korea. ( 30908740 )
2019
4
Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System: A Cluster Analysis. ( 30916724 )
2019
5
Family recurrence risk of alopecia areata in the Faroe Islands. ( 30929273 )
2019
6
Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report. ( 30938821 )
2019
7
Case of alopecia areata during dupilumab treatment for atopic dermatitis. ( 30942915 )
2019
8
Predictive factors of response to pulse methylprednisolone therapy in patients with alopecia areata: A follow-up study of 105 Japanese patients. ( 30969434 )
2019
9
Scalp bacterial shift in Alopecia areata. ( 30973913 )
2019
10
Alopecia areata is characterised by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. ( 30980732 )
2019
11
Identification of blood microRNA alterations in patients with severe active alopecia areata. ( 30983035 )
2019
12
Regulatory T-cells in alopecia areata. ( 30989699 )
2019
13
Serum Vitamin D Levels and Alopecia Areata- A Hospital Based Case-Control Study from North-India. ( 31007473 )
2019
14
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. ( 31008170 )
2019
15
The Association between Genetic Variation in Wnt Transcription Factor TCF7L2 (TCF4) and Alopecia Areata. ( 31012334 )
2019
16
Research letter: Retrospective outcome analysis of 25 alopecia areata patients treated with simvastatin/ezetimibe. ( 31015012 )
2019
17
A cross-sectional study of the histopathology and immunology of alopecia areata: Unearthing the role of the Janus kinase-signal transducer and activator of transcription pathway. ( 31031313 )
2019
18
Zwei Patienten mit Abheilung einer Alopecia areata unter Dupilumab. ( 31037851 )
2019
19
Reversible alopecia areata: a little known side effect of leflunomide. ( 31044385 )
2019
20
Cyclosporin for moderate to severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. ( 31048013 )
2019
21
Apremilast is efficacious in refractory alopecia areata. ( 31055978 )
2019
22
Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study. ( 31062723 )
2019
23
Evaluation of platelet-rich plasma vs intralesional steroid in treatment of alopecia areata. ( 31074201 )
2019
24
The profile of cytokines (IL-2, IFN-γ, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata. ( 31087753 )
2019
25
Patients with alopecia areata show signs of insulin resistance. ( 31089876 )
2019
26
The association between rs2476601 polymorphism in PTPN22 gene and risk of alopecia areata: A meta-analysis of case-control studies. ( 31096440 )
2019
27
Incidence and prevalence of alopecia areata according to subtype: A nationwide, population-based study in South Korea (2006-2015). ( 31102412 )
2019
28
Study on Serum Vitamin D in Alopecia Areata Patients. ( 31110371 )
2019
29
Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: A prospective, cross-sectional study. ( 30633941 )
2019
30
Dickkopf-1 Expression in Androgenetic Alopecia and Alopecia Areata in Male Patients. ( 30640755 )
2019
31
Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. ( 30649133 )
2019
32
Tinea Versicolor of the Neck As Side Effect of Topical Steroids For Alopecia Areata. ( 30668183 )
2019
33
Alopecia areata in Tunisia: epidemio-clinical aspects and comorbid conditions. A prospective study of 204 cases. ( 30677128 )
2019
34
The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature. ( 30688081 )
2019
35
Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients. ( 30693634 )
2019
36
JAK inhibitors and alopecia areata. ( 30696569 )
2019
37
Agreement Between Self-reported and Dermatologists' Diagnosis for Alopecia Areata and Atopic Dermatitis: A Bi-centric Prospective Study. ( 30723873 )
2019
38
Pathogenesis of Alopecia Areata Based on Bioinformatics Analysis. ( 30745627 )
2019
39
Alopecia Areata Different View; Heavy Metals. ( 30745628 )
2019
40
Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study. ( 30745629 )
2019
41
Efficacy and Safety of Methotrexate in Combination with Mini Pulse Doses of Methylprednisolone in Severe Alopecia Areata. The Vietnamese Experience. ( 30745958 )
2019
42
The Effectiveness of Oral Mini-Pulse Methylprednisolonein - the Treatment of Alopecia Areata in Vietnam. ( 30745983 )
2019
43
Ischemic modified albumin as a new biomarker in predicting oxidative stress in alopecia areata ( 30762322 )
2019
44
JAK inhibitors for alopecia areata: a systematic review and meta-analysis. ( 30762909 )
2019
45
Evaluation of Association of Vitamin D in Alopecia Areata: A Case-control Study of 100 Patients in a Tertiary Rural Hospital of Southern India. ( 30775298 )
2019
46
Differential expression patterns of specific long noncoding RNAs and competing endogenous RNA network in alopecia areata. ( 30790320 )
2019
47
Association of Out-of-Pocket Health Care Costs and Financial Burden for Patients With Alopecia Areata. ( 30810706 )
2019
48
Serum Interleukin-15 is a Marker of Alopecia Areata Severity. ( 30820130 )
2019
49
Alopecia Areata After Treatment With Dupilumab. ( 30829800 )
2019
50
Minoxidil for Patchy Alopecia Areata: Systematic Review and Meta-Analysis. ( 30835901 )
2019
Sources

Variations for Alopecia Areata

About this section

ClinVar genetic disease variations for Alopecia Areata:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(1;9;5)(compleX)dn Translocation Likely pathogenic
2 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Pathogenic/Likely pathogenic rs1057518972 GRCh38 Chromosome 8, 115418359: 115418359
3 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Pathogenic/Likely pathogenic rs1057518972 GRCh37 Chromosome 8, 116430587: 116430587
4 EMILIN2; LPIN2; METTL4; MYL12A; MYL12B; MYOM1; NDC80; SMCHD1; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance GRCh37 Chromosome 18, 1345040: 3479168
Sources

Expression for Alopecia Areata

About this section
Search GEO for disease gene expression data for Alopecia Areata.
Sources

Pathways for Alopecia Areata

About this section

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.04 CTLA4 CXCL10 FASLG ICAM1 IFNG IL17A
2
PEDF Induced Signaling 65
Show member pathways
 13.68 CXCL10 FASLG IFNG IL17A IL1A IL1RN
3
Akt Signaling 65
Show member pathways
 13.39 CXCL10 FASLG IL17A IL1A IL2 IL2RA
4
Cytokine Signaling in Immune system 67
Show member pathways
 13.35 CXCL10 FASLG ICAM1 IFNG IL17A IL1A
5
PAK Pathway 65
Show member pathways
 13.3 CXCL10 FASLG IL17A IL1A IL2 IL2RA
6
Allograft rejection 38 1
Show member pathways
 12.7 CTLA4 FASLG GZMB ICAM1 IFNG IL17A
7
Th17 cell differentiation 38
Show member pathways
 12.64 IFNG IL17A IL1A IL2 IL2RA TNF
8
T cell receptor signaling pathway 38
Show member pathways
 12.6 CTLA4 IFNG IL17A IL1A IL2 TNF
9
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.48 FASLG GZMB ICAM1 IFNG IL2 KLRK1
10
Human T-cell leukemia virus 1 infection 38
12.34 ICAM1 IL2 IL2RA TNF
11
Selenium Micronutrient Network 1
Show member pathways
 12.33 ICAM1 IFNG IL2 TNF
12
IL-17 Family Signaling Pathways 66
Show member pathways
 12.32 CXCL10 IFNG IL17A TNF
13
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.3 IFNG IL17A IL1A IL2 IL2RA TNF
14
Apoptosis and survival Caspase cascade 23
Show member pathways
 12.26 FASLG GZMB IL1A TNF
15
Necroptosis 38
Show member pathways
 12.22 FASLG IFNG IL1A TNF
16
Bacterial infections in CF airways 23
Show member pathways
 12.19 CXCL10 FASLG IFNG TNF
17
Immune response IFN gamma signaling pathway 23
Show member pathways
 12.12 ICAM1 IFNG IL17A IL1A IL2 IL2RA
18
Fluid shear stress and atherosclerosis 38
12.11 ICAM1 IFNG IL1A TNF
19
Th1 Differentiation Pathway 66
Show member pathways
 12.07 IFNG IL17A IL2 TNF
20
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.04 IFNG IL2 IL2RA KLRK1 TNF
21
Interleukin-4 and 13 signaling 67
12.02 FASLG ICAM1 IL17A IL1A TNF
22
IL12-mediated signaling events 1
Show member pathways
 12.01 FASLG GZMB IFNG IL2 IL2RA
23
Spinal Cord Injury 1
12.01 CXCL10 ICAM1 IFNG IL1A IL2 TNF
24
AGE-RAGE signaling pathway in diabetic complications 38
11.88 ICAM1 IL1A TNF
25
NF-kappaB Signaling 4
11.88 CTLA4 CXCL10 FASLG GZMB IFNG IL17A
26
Hematopoietic cell lineage 38
11.87 IL1A IL2RA TNF
27
Rheumatoid arthritis 38
11.87 CTLA4 ICAM1 IFNG IL17A IL1A TNF
28
Glucocorticoid receptor regulatory network 1
11.79 ICAM1 IFNG IL2
29
Dendritic Cells Developmental Lineage Pathway 66
11.74 IFNG IL2 TNF
30
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.73 CTLA4 FASLG IFNG IL2 IL2RA TNF
31
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.69 FASLG IL2 IL2RA
32
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.69 ICAM1 IFNG IL1A IL2 TNF
33
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.65 CXCL10 IFNG IL17A IL1RN IL2 TNF
34
Photodynamic therapy-induced AP-1 survival signaling. 1
11.62 FASLG IFNG IL2 TNF
35
Malaria 38
11.6 ICAM1 IFNG KLRK1 TNF
36
Interleukin-10 signaling 67
11.57 CXCL10 ICAM1 IL1A IL1RN TNF
37
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.55 FASLG IFNG IL1A TNF
38
Aryl Hydrocarbon Receptor Pathway 1
11.53 IFNG IL2 TNF
39
Th2 Differentiation Pathway 66
11.51 IFNG IL2 IL2RA
40
Immune response_Role of integrins in NK cells cytotoxicity 23
11.49 FASLG ICAM1 IFNG
41
African trypanosomiasis 38
11.42 FASLG ICAM1 IFNG TNF
42
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.42 FASLG GZMB IFNG IL2 IL2RA TNF
43
Type II interferon signaling (IFNG) 1
11.4 CXCL10 ICAM1 IFNG
44
Innate Lymphoid Cell Differentiation Pathways 66
11.4 GZMB IFNG IL17A IL2 IL2RA KLRK1
45
Inflammatory Response Pathway 1
11.34 IFNG IL2 IL2RA
46
Development and heterogeneity of the ILC family 1
11.32 IFNG IL17A TNF
47
Cytokines and Inflammatory Response 1
11.29 IFNG IL1A IL2 TNF
48
IL12 signaling mediated by STAT4 1
11.26 IFNG IL2 IL2RA
49
G-protein signaling_RhoB regulation pathway 23
11.22 CXCL10 FASLG IL17A IL1A IL2 TNF
50
G-protein signaling_Rap2B regulation pathway 23
11.03 CXCL10 FASLG IL17A IL1A IL2 TNF
Sources

GO Terms for Alopecia Areata

About this section

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CXCL10 FASLG ICAM1 IFNG IL17A IL1A
2 external side of plasma membrane GO:0009897 9.23 CTLA4 CXCL10 FASLG ICAM1 IL17A IL2RA

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CXCL10 IL17A IL1A IL1RN TNF
2 adaptive immune response GO:0002250 9.94 CTLA4 IFNG IL2 KLRK1
3 cell-cell signaling GO:0007267 9.92 CXCL10 FASLG IL17A IL2
4 response to lipopolysaccharide GO:0032496 9.88 CXCL10 FASLG ICAM1 PTPN22
5 regulation of signaling receptor activity GO:0010469 9.86 CXCL10 FASLG IFNG IL17A IL1A IL1RN
6 humoral immune response GO:0006959 9.79 AIRE IFNG TNF
7 cellular response to lipopolysaccharide GO:0071222 9.77 CXCL10 ICAM1 IL1RN KLRK1 TNF
8 extrinsic apoptotic signaling pathway GO:0097191 9.73 FASLG IFNG TNF
9 positive regulation of interferon-gamma production GO:0032729 9.72 IL2 KLRK1 TNF
10 natural killer cell activation GO:0030101 9.65 IL2 KLRK1 ULBP3
11 negative regulation of immune response GO:0050777 9.63 CTLA4 IL2RA
12 interleukin-2-mediated signaling pathway GO:0038110 9.63 IL2 IL2RA
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 ICAM1 IFNG KLRK1 TNF
14 necroptotic signaling pathway GO:0097527 9.61 FASLG TNF
15